Tag: "hodgkin" at biology news

FLT PET assesses treatment response on tumor growthnot sizewith non-Hodgkin's lymphoma

SAN DIEGO, Calif.--Positron emission tomography (PET)--with the radiolabeled thymidine analog [18F]Fluorothymidine (FLT)--is "a promising, sensitive tool" for assessing drug effects on tumor growth in patients with diffuse large B-cell lymphoma, according to a study released at SNM's 53rd Annual Meeting June 37 in San Diego.... ... "Conventional imaging modalities--such as computed tomography, ul...

BiovaxID yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) and its subsidiary, Biovest International, Inc. (OTCBB:BVTI), report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients. The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50...

PCBs, furans may factor in risk of non-Hodgkin lymphoma

Scientists have found some additional evidence that environmental exposure to polychlorinated biphenyls (PCBs) may be associated with non-Hodgkin lymphoma, according to a study published in the December 1 issue of Cancer Research....... By comparing blood levels of PCBs in 100 pairs of healthy volunteers and non-Hodgkin lymphoma patients, Anneclaire De Roos, Ph.D., assistant professor of epidemio...

Positive effects of nuclear medicine, 'smart drugs' provide hope for non-hodgkin's lymphoma patients

TORONTO, Canada--Three scientific studies--each highlighting new discoveries in treatment for patients with non-Hodgkin's lymphoma--were announced at the Society of Nuclear Medicine's 52nd Annual Meeting June 1822 in Toronto. ...... "Nuclear medicine has a growing role in treating non-Hodgkin's lymphoma," said SNM member Richard L. Wahl, M.D., director of nuclear medicine/PET at the Russell H. Mo...

Hepatitis C virus linked to non-Hodgkin's lymphoma

SEATTLE--Patients infected with the hepatitis C virus (HCV) are six times as likely to develop non-Hodgkin's lymphoma (NHL) than individuals that are virus free, according to research presented today at the Third Annual Frontiers in Cancer Prevention Research meeting.... HCV infected patients have a seventeen fold higher risk for developing diffuse large B-Cell lymphoma, researchers from British...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
Other Tags
beneficialbiotopesoybeanunraveldynastyshapirocarldarknessupmcultrasonographysnowmobiledisappearsranktherapyplateletcoagulants